Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 6, 2024, reports on interim clinical trial data announced by ViiV Healthcare, a global specialist HIV company majority-owned by GSK. The filing details results from the LATITUDE phase III trial presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical update and does not contain financial statements or performance metrics.
Material Changes and Clinical Results
The LATITUDE study compared long-acting injectable Cabenuva (cabotegravir + rilpivirine) against daily oral standard of care (SOC) in individuals with a history of adherence challenges. Key findings include:
- Regimen Failure: 24.1% in the long-acting arm versus 38.5% in the SOC arm (difference -14.4%).
- Virologic Failure: 7.2% in the long-acting arm versus 25.4% in the SOC arm (difference -18.2%).
- Treatment-Related Failure: 9.6% in the long-acting arm versus 26.2% in the SOC arm (difference -16.6%).
- DSMB Recommendation: The Data Safety Monitoring Board concluded the evidence indicated superior efficacy of the long-acting regimen and recommended offering it to all eligible participants.
Outlook, Risks, and Management Commentary
Management commentary from Kimberly Smith, MD, Head of Research & Development at ViiV Healthcare, highlights that one-third of people living with HIV in the U.S. struggle with viral suppression. The data suggests Cabenuva offers a critical option for this group to maintain viral control and reduce transmission risk. The study is ongoing across 31 U.S. sites. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2023 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the commercial impact of the LATITUDE results on Cabenuva sales projections and market share in the HIV treatment sector.
- Confirm the timeline for regulatory submissions or label expansions based on the DSMB's recommendation.
- Review the safety profile details regarding injection site reactions (ISRs) and resistance-associated mutations (RAMs) mentioned in the trial.
- Assess the ownership structure and financial contribution of ViiV Healthcare to GSK's overall portfolio.